2024-11-12 - Analysis Report
##  Johnson & Johnson (JNJ) Stock Analysis Report 

**1. Performance Comparison:**

Johnson & Johnson (JNJ) is a multinational pharmaceutical, medical device, and consumer packaged goods company.

| Year | JNJ CAGR | VOO CAGR | JNJ Alpha | JNJ Beta | JNJ Market Cap (B) |
|---|---|---|---|---|---|
| 2015-2017 | 33.7% | N/A | 3.5% | 0.7 | 336.39 |
| 2016-2018 | 28.4% | N/A | 3.8% | 0.7 | 310.70 |
| 2017-2019 | 25.9% | N/A | -17.1% | 0.7 | 351.20 |
| 2018-2020 | 13.0% | N/A | -26.1% | 0.7 | 378.91 |
| 2019-2021 | 33.9% | N/A | -55.9% | 0.6 | 411.87 |
| 2020-2022 | 21.0% | N/A | 3.3% | 0.5 | 425.31 |
| 2021-2023 | 0.1% | N/A | -28.7% | 0.3 | 377.37 |
| 2022-2024 | -9.4% | N/A | -34.6% | 0.2 | 377.35 |

**Analysis:** JNJ has underperformed the S&P 500 (VOO) by a significant margin (-113.22%). This can be attributed to several factors, including the recent spin-off of the consumer health division, regulatory scrutiny, and macroeconomic headwinds. The Alpha analysis suggests that JNJ has generated above-market returns in some years, but has also significantly underperformed in others. The Beta analysis indicates that JNJ's stock price is less volatile than the overall market.

**2. Recent Price Action:**

* Last-market: 155.85
* Closing price: 155.47
* 5-day moving average: 157.33
* 20-day moving average: 161.26
* 60-day moving average: 162.55

**Analysis:** JNJ is currently trading below its 5-day, 20-day, and 60-day moving averages, indicating a bearish trend. 

**3. Technical Indicators:**

* RSI: 27.91
* PPO: -0.41
* 20-day relative divergence change: -3.93

**Analysis:** The RSI suggests that JNJ is currently oversold. The PPO indicates a weakening momentum. The recent 20-day relative divergence change suggests that JNJ has experienced a short-term decline.

**Expected Return:** 0.0%.  This indicates that JNJ is not expected to outperform the S&P 500 over the long term (2 years or more).

**4. Recent Earnings and Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-10-23 | 1.12 | 22.47 B$ |
| 2024-07-25 | 1.95 | 22.45 B$ |
| 2024-05-01 | 1.35 | 21.38 B$ |
| 2024-02-16 | 1.68 | 21.39 B$ |
| 2023-10-27 | 10.32 | 21.35 B$ |

**Analysis:** JNJ has shown a trend of lower earnings in recent quarters. While the company is expected to continue its growth in the medical device and pharmaceuticals segments, the spin-off of the consumer health division is likely to impact earnings going forward.  More specific analysis of the recent earnings call is needed to assess expectations and potential impact on future performance.

**5. Financial Information:**

**Revenue and Profitability:**

| Quarter | Revenue | Profit Margin |
|---|---|---|
| 2024-09-30 | $22.47B | 69.01% |
| 2024-06-30 | $22.45B | 69.40% |
| 2024-03-31 | $21.38B | 69.55% |
| 2023-12-31 | $21.39B | 68.23% |
| 2023-09-30 | $21.35B | 69.06% |

**Capital and Profitability:**

| Quarter | Equity | ROE |
|---|---|---|
| 2024-09-30 | $70.16B | 3.84% |
| 2024-06-30 | $71.54B | 6.55% |
| 2024-03-31 | $70.02B | 4.65% |
| 2023-12-31 | $68.77B | 5.89% |
| 2023-09-30 | $71.23B | 36.54% |

**Analysis:** JNJ maintains a strong financial position with consistent revenue and high profitability. While the ROE has experienced fluctuations, it remains at a healthy level. The recent spin-off of the consumer health division might have a slight impact on these metrics in the upcoming quarters.

**6. News and Recent Issues:**

* **Recent Earnings Call:** JNJ's recent earnings call is expected to shed light on the company's future outlook. Look for any comments regarding the spin-off, growth in medical device and pharmaceuticals, and any potential regulatory hurdles.
* **Market Outlook:** Analysts remain divided on JNJ's outlook. Some see potential for growth in the medical device and pharmaceutical segments, while others remain cautious due to the spin-off and the challenging macroeconomic environment. 
* **Analyst Opinions:** Refer to FINBOLD or other financial news sources for detailed analyst ratings and target prices.

**7.  Overall Analysis:**

Johnson & Johnson remains a well-established and financially strong company with a long history of providing quality healthcare products and services. However, the recent spin-off, regulatory scrutiny, and the challenging macroeconomic environment pose significant challenges for the company. 

Despite recent underperformance, JNJ's strong financial position and focus on medical devices and pharmaceuticals could create long-term value for investors. 

**Recommendation:** While JNJ is currently trading at a discount to its historical valuation, the recent underperformance and uncertain future outlook warrant a cautious approach. Investors should consider the company's long-term potential, and the potential impact of the spin-off on its future performance, before making any investment decisions.

**Note:** This is a simplified analysis. Investors should conduct their own research and consult with a financial advisor before making any investment decisions. 
